Previous 10 | Next 10 |
2024-05-09 00:31:25 ET Summary Health Care sector performance in the S&P 500 has been mixed, with some companies struggling while Eli Lilly dominates amid a focus on GLP-1s. Edwards Lifesciences Corporation is a leader in the transcatheter heart valve replacement market and fe...
Edwards Lifesciences today announced the European launch of the SAPIEN 3 Ultra RESILIA valve, the only transcatheter aortic heart valve to incorporate the company’s breakthrough RESILIA tissue technology, designed to extend the valve’s durability.* Edwards’ SAPIEN 3 Ultra...
2024-05-06 21:30:02 ET Barclays analyst issues OVERWEIGHT recommendation for EW on May 6, 2024 08:09PM ET. The previous analyst recommendation was Overweight. EW was trading at $85.09 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curren...
2024-05-05 15:10:28 ET More on the markets S&P 500 1%+ Gaps Higher SPY: Don't Buy The Dip Just Yet Rate Hike Unlikely: Expect S&P 500 To Rally To New All-Time Highs Data Insight: April's jobs report was biggest disappointment in at least 2 years ...
2024-04-25 21:19:07 ET Edwards Lifesciences Corporation (EW) Q1 2024 Earnings Conference Call April 25, 2024 05:00 PM ET Company Participants Mark Wilterding - SVP & IR Bernard Zovighian - CEO Scott Ullem - CFO Daveen Chopra - Global Leader of TMTT La...
2024-04-25 16:18:53 ET More on Edwards Lifesciences Read the full article on Seeking Alpha For further details see: Edwards Lifesciences Non-GAAP EPS of $0.66 beats by $0.02, revenue of $1.6B beats by $30M
Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...
2024-04-24 17:20:27 ET More on Edwards Lifesciences Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained) Edwards Lifesciences Corporation (EW) Q4 2023 Earnings Call Transcript BofA upgrades Edwards to buy, says double-digit growth is ...
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877...
2024-04-15 10:00:02 ET Shagun Singh from RBC Capital issued a price target of $101.00 for EW on 2024-04-15 08:08:00. The adjusted price target was set to $101.00. At the time of the announcement, EW was trading at $90.28. The overall price target consensus is at $111.78 ...
News, Short Squeeze, Breakout and More Instantly...
Edwards Lifesciences Corporation Company Name:
EW Stock Symbol:
NYSE Market:
Edwards Lifesciences Corporation Website:
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2024 after the market closes on Wednesday, July 24, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877)...
Edwards Lifesciences (NYSE: EW) today announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve replacement (TMVR) company, following its initial investment in 2017. Since that time, Innovalve has demonstrated progress in its program wi...
2024-07-08 19:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...